M
Meenhard Herlyn
Researcher at Wistar Institute
Publications - 29
Citations - 6085
Meenhard Herlyn is an academic researcher from Wistar Institute. The author has contributed to research in topics: Melanoma & Immune checkpoint. The author has an hindex of 24, co-authored 29 publications receiving 4092 citations.
Papers
More filters
Journal ArticleDOI
Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
Chen Gang,Alexander C. Huang,Wei Zhang,Wei Zhang,Gao Zhang,Wu Min,Wei Xu,Zi-Li Yu,Jiegang Yang,Jiegang Yang,Beike Wang,Beike Wang,Honghong Sun,Hou-Fu Xia,Qiwen Man,Wenqun Zhong,Wenqun Zhong,Leonardo F. Antelo,Bin Wu,Xuepeng Xiong,Xiaoming Liu,Lei Guan,Lei Guan,Ting Li,Ting Li,Shujing Liu,Ruifeng Yang,Youtao Lu,Liyun Dong,Suzanne McGettigan,Rajasekharan Somasundaram,Ravi Radhakrishnan,Gordon B. Mills,Yiling Lu,Junhyong Kim,Youhai H. Chen,Haidong Dong,Yi-Fang Zhao,Giorgos C. Karakousis,Tara C. Mitchell,Lynn M. Schuchter,Meenhard Herlyn,E. John Wherry,Xiaowei Xu,Wei Guo +44 more
TL;DR: It is reported that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface, suggesting a mechanism by which tumours could evade the immunesystem, and the potential application ofExosomal PD- L1 to monitor patient responses to checkpoint therapies.
Journal ArticleDOI
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon,Parin Shah,Michael S. Cuoco,Christopher Rodman,Mei-Ju Su,Johannes C. Melms,Rachel Leeson,Abhay Kanodia,Shaolin Mei,Jia-Ren Lin,Shu Wang,Bokang Rabasha,David Liu,Gao Zhang,Claire Margolais,Orr Ashenberg,Patrick A. Ott,Elizabeth I. Buchbinder,Rizwan Haq,F. Stephen Hodi,Genevieve M. Boland,Ryan J. Sullivan,Dennie T. Frederick,Benchun Miao,Tabea Moll,Keith T. Flaherty,Meenhard Herlyn,Russell W. Jenkins,Rohit Thummalapalli,Monika S. Kowalczyk,Israel Cañadas,Bastian Schilling,Bastian Schilling,Adam N.R. Cartwright,Adrienne M. Luoma,Shruti Malu,Patrick Hwu,Chantale Bernatchez,Marie Andrée Forget,David A. Barbie,Alex K. Shalek,Itay Tirosh,Peter K. Sorger,Kai W. Wucherpfennig,Eliezer M. Van Allen,Dirk Schadendorf,Bruce E. Johnson,Asaf Rotem,Asaf Rotem,Orit Rozenblatt-Rosen,Levi A. Garraway,Charles H. Yoon,Charles H. Yoon,Benjamin Izar,Aviv Regev +54 more
TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.
Journal ArticleDOI
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander,Gao Zhang,Joo Sang Lee,Joo Sang Lee,Dennie T. Frederick,Benchun Miao,Tabea Moll,Tian Tian,Zhi Wei,Sanna Madan,Sanna Madan,Ryan J. Sullivan,Genevieve M. Boland,Keith T. Flaherty,Meenhard Herlyn,Eytan Ruppin,Eytan Ruppin +16 more
TL;DR: IMPRES is a predictor of ICB response in melanoma which encompasses 15 pairwise transcriptomics relations between immune checkpoint genes and achieves an overall accuracy of AUC = 0.83, outperforming existing predictors and capturing almost all true responders while misclassifying less than half of the nonresponders.
Journal ArticleDOI
Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
Xiao Hong Ma,Sheng Fu Piao,Souvik Dey,Quentin McAfee,Giorgos C. Karakousis,Jessie Villanueva,Lori S. Hart,Samuel M. Levi,Janice Hu,Gao Zhang,Rossitza Lazova,Vincent Klump,John M. Pawelek,Xiaowei Xu,Wei Xu,Lynn M. Schuchter,Michael A. Davies,Meenhard Herlyn,Jeffrey D. Winkler,Constantinos Koumenis,Ravi K. Amaravadi +20 more
TL;DR: Using tumor biopsies from BRAF(V600E) melanoma patients treated either with BRAFi or with combined BRAF and MEK inhibition, it is found that BRAFi-resistant tumors had increased levels of autophagy compared with baseline and a rationale for combination approaches targeting this resistance pathway is provided.
Journal ArticleDOI
Enhancing CD8 + T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.
Ying Zhang,Ying Zhang,Raj K. Kurupati,Ling Liu,Xiangyang Zhou,Gao Zhang,Abeer Hudaihed,Flavia Filisio,Wynetta Giles-Davis,Xiaowei Xu,Giorgos C. Karakousis,Lynn M. Schuchter,Wei Xu,Ravi K. Amaravadi,Min Xiao,Norah Sadek,Clemens Krepler,Meenhard Herlyn,Gordon J. Freeman,Joshua D. Rabinowitz,Hildegund C.J. Ertl +20 more
TL;DR: Using mouse melanoma models, it is reported that CD8+ TILs enhance peroxisome proliferator-activated receptor (PPAR)-α signaling and catabolism of fatty acids (FAs) when simultaneously subjected to hypoglycemia and hypoxia.